{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:47:17Z","timestamp":1785883637743,"version":"3.56.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00774-021-01276-5","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T09:17:11Z","timestamp":1642497431000},"page":"275-291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Long-term safety of eldecalcitol in Japanese patients with osteoporosis: a retrospective, large-scale database study"],"prefix":"10.1007","volume":"40","author":[{"given":"Yasuhiro","family":"Takeuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misako","family":"Makishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Isemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"key":"1276_CR1","doi-asserted-by":"crossref","unstructured":"Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, E V McCloskey EV, B J\u00f6nsson B, J A Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8: 136","DOI":"10.1007\/s11657-013-0136-1"},{"key":"1276_CR2","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.bone.2011.07.011","volume":"49","author":"T Matsumoto","year":"2011","unstructured":"Matsumoto T, Ito M, Hayashi Y, Hirota T, Tanigawara Y, Sone T, Fukunaga M, Shiraki M, Nakamura T (2011) A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures\u2013a randomized, active comparator, double-blind study. Bone 49:605\u2013612","journal-title":"Bone"},{"key":"1276_CR3","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00198-017-4351-2","volume":"29","author":"K Uenishi","year":"2018","unstructured":"Uenishi K, Tokiwa M, Kato S, Shiraki M (2018) Stimulation of intestinal calcium absorption by orally administrated vitamin D3 compounds: a prospective open-label randomized trial in osteoporosis. Osteoporos Int 29:723\u2013732","journal-title":"Osteoporos Int"},{"key":"1276_CR4","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s00198-014-2991-z","volume":"26","author":"Sakai A, Ito M, Tomomitsu T, Tsurukami H, Ikeda S, Fukuda F, Mizunuma H, Inoue T, Saito H, Nakamura T; e-ADVANCED Study Group","year":"2015","unstructured":"Sakai A, Ito M, Tomomitsu T, Tsurukami H, Ikeda S, Fukuda F, Mizunuma H, Inoue T, Saito H, Nakamura T; e-ADVANCED Study Group (2015) Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis. Osteoporos Int 26:1193\u20131202","journal-title":"Osteoporos Int"},{"key":"1276_CR5","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/s00774-016-0779-2","volume":"35","author":"H Saito","year":"2017","unstructured":"Saito H, Kakihata H, Nishida Y, Yatomi S, Nihojima S, Kobayashi Y, Tabata H, Nomura M (2017) The safety and effectiveness profile of eldecalcitol in a prospective, post-marketing observational study in Japanese patients with osteoporosis: interim report. J Bone Miner Metab 35:456\u2013463","journal-title":"J Bone Miner Metab"},{"key":"1276_CR6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1080\/0886022X.2019.1578667","volume":"41","author":"S Aihara","year":"2019","unstructured":"Aihara S, Yamada S, Oka H, Kamimura T, Nakano T, Tsuruya K, Harada A (2019) Hypercalcemia and acute kidney injury induced by eldecalcitol in patients with osteoporosis: a case series of 32 patients at a single facility. Ren Fail 41:88\u201397","journal-title":"Ren Fail"},{"key":"1276_CR7","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115\u20131117","journal-title":"J Oral Maxillofac Surg"},{"key":"1276_CR8","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132\u20135139","journal-title":"J Clin Oncol"},{"key":"1276_CR9","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Dami\u00e3o R, Brown J et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet (London, England) 377:813\u2013822","journal-title":"Lancet (London, England)"},{"key":"1276_CR10","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V et al (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125\u20131132","journal-title":"J Clin Oncol"},{"key":"1276_CR11","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.14219\/jada.archive.2011.0108","volume":"142","author":"JW Hellstein","year":"2011","unstructured":"Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, Koka S, Migliorati CA, Ristic H (2011) American Dental Association Council on Scientific Affairs Expert Panel on Antiresorptive Agents: Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 142:1243\u20131251","journal-title":"J Am Dent Assoc"},{"key":"1276_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK et al (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30:3\u201323","journal-title":"J Bone Miner Res"},{"key":"1276_CR13","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1016\/j.joms.2011.03.051","volume":"69","author":"M Urade","year":"2011","unstructured":"Urade M, Tanaka N, Furusawa K, Shimada J, Shibata T, Kirita T, Yamamoto T, Ikebe T, Kitagawa Y, Fukuta J (2011) Nationwide survey for bisphosphonate-related osteonecrosis of the jaws in Japan. J Oral Maxillofac Surg 69:e364-371","journal-title":"J Oral Maxillofac Surg"},{"key":"1276_CR14","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1016\/j.joms.2018.04.009","volume":"76","author":"T Shibahara","year":"2018","unstructured":"Shibahara T, Morikawa T, Yago K, Kishimoto H, Imai Y, Kurita K (2018) National Survey on Bisphosphonate Related Osteonecrosis of the Jaws in Japan. J Oral Maxillofac Surg 76:2105\u20132112","journal-title":"J Oral Maxillofac Surg"},{"key":"1276_CR15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00774-016-0810-7","volume":"35","author":"T Yoneda","year":"2017","unstructured":"Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S et al (2017) Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab 35:6\u201319","journal-title":"J Bone Miner Metab"},{"key":"1276_CR16","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1080\/14397595.2017.1308454","volume":"28","author":"T Suzuki","year":"2018","unstructured":"Suzuki T, Nakamura Y, Tanaka M, Kamimura M, Ikegami S, Uchiyama S, Kato H (2018) Comparison of the effects of denosumab with either active vitamin D or native vitamin D on bone mineral density and bone turnover markers in postmenopausal osteoporosis. Modern Rheumatol 28:376\u2013379","journal-title":"Modern Rheumatol"},{"key":"1276_CR17","first-page":"879","volume":"85","author":"H Hagino","year":"2011","unstructured":"Hagino H (2011) Committee report: results of the survey on atypical femur fracture cases. J Jpn Orthop Assoc 85:879\u2013884","journal-title":"J Jpn Orthop Assoc"},{"key":"1276_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.1998","volume":"29","author":"E Shane","year":"2014","unstructured":"Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD et al (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1\u201323","journal-title":"J Bone Miner Res"},{"key":"1276_CR19","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/jbmr.3017","volume":"32","author":"HY Kim","year":"2017","unstructured":"Kim HY, Kim JW, Kim SJ, Lee SH, Lee HS (2017) Uncertainty of current algorithm for bisphosphonate-related osteonecrosis of the jaw in population-based studies: a systematic review. J Bone Miner Res 32:584\u2013591","journal-title":"J Bone Miner Res"},{"key":"1276_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3820\/jjpe.21.13","volume":"21","author":"S Tanaka","year":"2016","unstructured":"Tanaka S, Hagino H, Ishizuka A, Miyazaki T, Yamamoto T, Hosoi T (2016) Validation study of claims-based definitions of suspected atypical femoral fractures using clinical information. Jpn J Pharmacoepidemiol 21:13\u201319","journal-title":"Jpn J Pharmacoepidemiol"},{"key":"1276_CR21","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s10157-007-0463-x","volume":"11","author":"E Imai","year":"2007","unstructured":"Imai E, Horio M, Iseki K, Yamagata K, Watanabe T et al (2007) Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol 11:156\u2013163","journal-title":"Clin Exp Nephrol"},{"key":"1276_CR22","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/ki.1990.87","volume":"37","author":"S Rosen","year":"1990","unstructured":"Rosen S, Greenfeld Z, Bernheim J, Rathaus M, Podjarny E, Brezis M (1990) Hypercalcemic nephropathy: chronic disease with predominant medullary inner stripe injury. Kidney Int 37:1067\u20131075","journal-title":"Kidney Int"},{"key":"1276_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.urology.2007.09.034","volume":"71","author":"T Yasui","year":"2008","unstructured":"Yasui T, Iguchi M, Suzuki S, Kohri K (2008) Prevalence and epidemiological characteristics of urolithiasis in Japan: national trends between 1965 and 2005. Urology 71:209\u2013213","journal-title":"Urology"},{"key":"1276_CR24","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3945\/ajcn.110.003350","volume":"94","author":"RB Wallace","year":"2011","unstructured":"Wallace RB, Wactawski-Wende J, O\u2019Sullivan MJ, Larson JC, Cochrane B, Gass M, Masaki K (2011) Urinary tract stone occurrence in the Women\u2019s Health Initiative (WHI) randomized clinical trial of calcium and vitamin D supplements. Am J Clin Nutr 94:270\u2013277","journal-title":"Am J Clin Nutr"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-021-01276-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-021-01276-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-021-01276-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T09:10:19Z","timestamp":1646817019000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-021-01276-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1276"],"URL":"https:\/\/doi.org\/10.1007\/s00774-021-01276-5","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,18]]},"assertion":[{"value":"31 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work is funded by Chugai Pharmaceutical Co. Ltd. (UMIN000041937). YT has received personal fees from Chugai Pharmaceutical Co. Ltd., during the conduct of the study. SK, MM, TY, HY, and HS are employees of Chugai Pharmaceutical Co. Ltd. EI, HF, and TI are employees of Intage Healthcare Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}